JO2822B1 - Inhibitors of the enzyme kinase P70 S6 and AKT - Google Patents

Inhibitors of the enzyme kinase P70 S6 and AKT

Info

Publication number
JO2822B1
JO2822B1 JO2009400A JOP20090400A JO2822B1 JO 2822 B1 JO2822 B1 JO 2822B1 JO 2009400 A JO2009400 A JO 2009400A JO P20090400 A JOP20090400 A JO P20090400A JO 2822 B1 JO2822 B1 JO 2822B1
Authority
JO
Jordan
Prior art keywords
kinase inhibitors
formula
70akt
compounds
present
Prior art date
Application number
JO2009400A
Other languages
Arabic (ar)
English (en)
Inventor
دين دالي روبرت
الان شيبرد تيموثي
جوزيف ساجان
Original Assignee
ايلي ليلي اند كومباني
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ايلي ليلي اند كومباني filed Critical ايلي ليلي اند كومباني
Application granted granted Critical
Publication of JO2822B1 publication Critical patent/JO2822B1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pulmonology (AREA)
  • Emergency Medicine (AREA)
  • Reproductive Health (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JO2009400A 2008-11-11 2009-10-29 Inhibitors of the enzyme kinase P70 S6 and AKT JO2822B1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US11327308P 2008-11-11 2008-11-11

Publications (1)

Publication Number Publication Date
JO2822B1 true JO2822B1 (en) 2014-09-15

Family

ID=41402451

Family Applications (1)

Application Number Title Priority Date Filing Date
JO2009400A JO2822B1 (en) 2008-11-11 2009-10-29 Inhibitors of the enzyme kinase P70 S6 and AKT

Country Status (36)

Country Link
US (1) US8148387B2 (Direct)
EP (1) EP2358710B1 (Direct)
JP (1) JP5432275B2 (Direct)
KR (1) KR101334460B1 (Direct)
CN (1) CN102216302B (Direct)
AR (1) AR074072A1 (Direct)
AU (1) AU2009314324B2 (Direct)
BR (1) BRPI0921916A2 (Direct)
CA (1) CA2743019C (Direct)
CO (1) CO6382114A2 (Direct)
CR (1) CR20110240A (Direct)
CY (1) CY1113409T1 (Direct)
DK (1) DK2358710T3 (Direct)
DO (1) DOP2011000129A (Direct)
EA (1) EA018947B1 (Direct)
EC (1) ECSP11011048A (Direct)
ES (1) ES2391704T3 (Direct)
HN (1) HN2011001247A (Direct)
HR (1) HRP20120738T1 (Direct)
IL (1) IL211940A (Direct)
JO (1) JO2822B1 (Direct)
MA (1) MA32776B1 (Direct)
MX (1) MX2011005000A (Direct)
MY (1) MY161461A (Direct)
NZ (1) NZ592062A (Direct)
PA (1) PA8846901A1 (Direct)
PE (1) PE20110807A1 (Direct)
PL (1) PL2358710T3 (Direct)
PT (1) PT2358710E (Direct)
RS (1) RS52520B (Direct)
SI (1) SI2358710T1 (Direct)
TN (1) TN2011000207A1 (Direct)
TW (1) TWI422587B (Direct)
UA (1) UA100190C2 (Direct)
WO (1) WO2010056563A1 (Direct)
ZA (1) ZA201102549B (Direct)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20120106714A (ko) 2009-07-02 2012-09-26 사노피 신규 (6-옥소-1,6-디히드로-피리미딘-2-일)아미드 유도체, 그의 제조법, 및 ａｋｔ(ｐｋｂ) 인산화 억제제로서의 그의 제약 용도
MX2012004780A (es) * 2009-10-23 2012-08-23 Lilly Co Eli Inhibidores de akt.
HUE026323T2 (en) 2011-04-07 2016-05-30 Bayer Ip Gmbh Imidazopyridazines as akt kinase inhibitors
US8927572B2 (en) * 2011-07-09 2015-01-06 Xuanzhu Pharma Co., Ltd. Crystal form I of salt of a dipeptidyl peptidase-IV inhibitor and preparation method and use thereof
WO2013040059A1 (en) 2011-09-12 2013-03-21 Merck Patent Gmbh Novel imidazole amines as modulators of kinase activity
WO2013040044A1 (en) 2011-09-12 2013-03-21 Merck Patent Gmbh Aminopyrimidine derivatives for use as modulators of kinase activity
AR093512A1 (es) 2012-11-16 2015-06-10 Merck Patent Gmbh Derivados heterociclicos como moduladores de la actividad de cinasas
WO2014078634A1 (en) 2012-11-16 2014-05-22 Merck Patent Gmbh Novel imidazol-piperidinyl derivatives as modulators of kinase activity
WO2014143612A1 (en) * 2013-03-11 2014-09-18 Merck Patent Gmbh 6-[4-(1 h-imidazol-2-yl)piperidin-1 -yl]pyrimidin-4-amine derivatives as modulators of kinase activity
MX2016010268A (es) * 2014-02-11 2016-10-13 Merck Patent Gmbh Pirimidinimidazolaminas como modulares de actividad de cinasa.
TW201718574A (zh) 2015-08-12 2017-06-01 美國禮來大藥廠 Ｃｇｒｐ受體拮抗劑
WO2017200087A1 (ja) * 2016-05-20 2017-11-23 大鵬薬品工業株式会社 新規５Ｈ－ピロロ［２，３－ｄ］ピリミジン－６（７Ｈ）－オン誘導体
MX2022011188A (es) 2020-03-17 2022-11-08 Jiangsu Hengrui Pharmaceuticals Co Ltd Derivado biciclico fusionado, metodo de preparacion y uso farmaceutico del mismo.
CN113444110B (zh) * 2020-03-25 2023-05-12 江苏恒瑞医药股份有限公司 四氢吡咯并吡唑类衍生物、其制备方法及其在医药上的应用
JP2024535857A (ja) 2021-09-17 2024-10-02 江▲蘇▼恒瑞医▲薬▼股▲フン▼有限公司 縮合二環系誘導体の薬学的に許容される塩、結晶及びそれらの調製方法
JPWO2024009977A1 (Direct) * 2022-07-05 2024-01-11

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005249380C1 (en) 2004-04-23 2012-09-20 Exelixis, Inc. Kinase modulators and methods of use
MY179032A (en) 2004-10-25 2020-10-26 Cancer Research Tech Ltd Ortho-condensed pyridine and pyrimidine derivatives (e.g.purines) as protein kinase inhibitors
WO2006071819A1 (en) 2004-12-28 2006-07-06 Exelixis, Inc. [1h-pyrazolo[3, 4-d]pyrimidin-4-yl]-piperidine or -piperazine compounds as serine-theoronine kinase modulators (p70s6k, atk1 and atk2) for the treatment of immunological, inflammatory and proliferative diseases
US7423043B2 (en) * 2005-02-18 2008-09-09 Lexicon Pharmaceuticals, Inc. 4-Piperidin-1-yl-7H-pyrrolo[2,3-d]pyrimidine compounds
US20090325924A1 (en) 2005-06-30 2009-12-31 Stuart Edward GPCR Agonists
EP2037931A2 (en) 2006-04-25 2009-03-25 Astex Therapeutics Limited Pharmaceutical combinations of pk inhibitors and other active agents
FI3719018T3 (fi) 2006-04-25 2025-10-07 Astex Therapeutics Ltd Puriini- ja deatsapuriinijohdannaisia farmaseuttisina yhdisteinä
WO2008012635A2 (en) 2006-07-26 2008-01-31 Pfizer Products Inc. Amine derivatives useful as anticancer agents
AR064416A1 (es) * 2006-12-21 2009-04-01 Cancer Rec Tech Ltd Derivados de purina, piridina y pirimidina condensadas con heterociclos, moduladores de pka y/o pkb, composiciones farmaceuticas que los contienen, y usos para el tratamiento de enfermedades hiperproliferativas.
UA99284C2 (ru) 2007-05-11 2012-08-10 Елі Ліллі Енд Компані ИНГИБИТОРЫ р70 S6-КИНАЗЫ

Also Published As

Publication number Publication date
JP5432275B2 (ja) 2014-03-05
KR101334460B1 (ko) 2013-12-02
AR074072A1 (es) 2010-12-22
EP2358710B1 (en) 2012-08-15
WO2010056563A1 (en) 2010-05-20
PL2358710T3 (pl) 2012-12-31
EP2358710A1 (en) 2011-08-24
TWI422587B (zh) 2014-01-11
PT2358710E (pt) 2012-10-01
SI2358710T1 (sl) 2012-11-30
KR20110074578A (ko) 2011-06-30
CN102216302A (zh) 2011-10-12
US8148387B2 (en) 2012-04-03
HN2011001247A (es) 2013-05-20
ES2391704T3 (es) 2012-11-29
MA32776B1 (fr) 2011-11-01
MY161461A (en) 2017-04-14
AU2009314324B2 (en) 2013-06-20
RS52520B (sr) 2013-04-30
BRPI0921916A2 (pt) 2015-12-29
DOP2011000129A (es) 2016-02-29
ZA201102549B (en) 2012-09-26
TW201022268A (en) 2010-06-16
EA018947B1 (ru) 2013-11-29
JP2012508274A (ja) 2012-04-05
CO6382114A2 (es) 2012-02-15
IL211940A0 (en) 2011-06-30
TN2011000207A1 (en) 2012-12-17
HRP20120738T1 (hr) 2012-10-31
PA8846901A1 (es) 2010-06-28
UA100190C2 (en) 2012-11-26
CA2743019C (en) 2013-08-13
IL211940A (en) 2014-01-30
US20100120801A1 (en) 2010-05-13
NZ592062A (en) 2013-03-28
EA201170680A1 (ru) 2011-12-30
AU2009314324A1 (en) 2010-05-20
CN102216302B (zh) 2013-08-21
MX2011005000A (es) 2011-05-25
ECSP11011048A (es) 2011-06-30
DK2358710T3 (da) 2012-09-03
CY1113409T1 (el) 2016-06-22
CR20110240A (es) 2011-06-09
PE20110807A1 (es) 2011-10-31
CA2743019A1 (en) 2010-05-20
HK1158203A1 (en) 2012-07-13

Similar Documents

Publication Publication Date Title
JO2822B1 (en) Inhibitors of the enzyme kinase P70 S6 and AKT
MY154898A (en) P70 s6 kinase inhibitors
MX2012004780A (es) Inhibidores de akt.
SG179085A1 (en) Pi3 kinase inhibitors and uses thereof
PH12015501484A1 (en) Heteroaryl compounds and uses thereof
TW201713640A (en) Bruton's tyrosine kinase inhibitors
MY153915A (en) Organic compounds
TN2010000131A1 (en) Polo-like kinase inhibitors
MY148634A (en) Pyridazinone derivatives
PH12012501346A1 (en) Heteroaryl compounds and uses thereof
PH12013500870A1 (en) Heterocyclic compounds and uses thereof
WO2012122383A3 (en) Pi3 kinase inhibitors and uses thereof
MY150542A (en) Cmet inhibitors
WO2010048358A3 (en) Ethoxyphenylmethyl inhibitors of sglt2
EA201071224A1 (ru) Ингибиторы limk2, композиции, содержащие их, и способы их применения
GEP20156242B (en) 2-arylimidazole derivatives as pde10a enzyme inhibitors
PL1761520T3 (pl) Inhibitory kinazy
GEP20166481B (en) (crystalline forms of hydrochloride salt of (4a-r, 9a-s)-1-(1h-benzoimidazole-5-carbonyl)-2, 3, 4, 4a, 9, 9a-hexa- hydro-1h-indeno [2, 1-b] pyridine-6-carbonitrile and their use as hsd 1 inhibitors
WO2009094560A3 (en) Thienopyranones as kinase inhibitors
UA85505C2 (en) Kinase inhibitors
WO2010059639A3 (en) Hydroxyadamantyl inhibitors of dipeptidylpeptidase iv
MX2009003793A (es) Inhibidores de cinasa.
UA99739C2 (ru) Ингибиторы polo-подобных киназ
TN2010000583A1 (en) Organic compounds